Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
Steven LawAviva PetrieLiza ChackoOliver C CohenSriram RavichandranJanet A GilbertsonDorota RowczenioAshutosh WechalekarAna Martinez-NaharroHelen J LachmannCarol J WhelanDavid F HuttPhilip N HawkinsMarianna FontanaJulian D GillmorePublished in: ESC heart failure (2020)
National Amyloidosis Centre ATTR stage predicts ongoing survival throughout the disease natural history in ATTR-CM, and an increase from NAC ATTR Stage I at diagnosis to a higher NAC ATTR stage predicts mortality throughout follow-up. Serial calculation of NAC ATTR stage suggests a more aggressive phenotype in V122I-hATTR-CM than in wtATTR-CM.